France’s Servier has established a three-year strategic research alliance with Harvard University to support multiple, multi-year research projects that will focus on the development of innovative therapeutics across Servier’s areas of expertise.
The alliance represents a major milestone in non-profit foundation governed Servier’s ambition to build a footprint in the Boston and Cambridge research hub.
Under the new research alliance, coordinated by Harvard’s Office of Technology Development, Servier will support a number of faculty-initiated research projects at Harvard, identifying these projects through a request for proposals in two funding cycles. Harvard and Servier anticipate a range of projects spanning exploratory investigations of biological mechanisms, to identification of possible targets, or to preclinical validation of targets and leads.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze